News by subject: TRI

A new study by Hospital for Special Surgery (HSS) investigators has found that an initial high-risk antibody profile for antiphospholipid syndrome (APS) tended to remain high in pediatric patients. The results were presented today in a poster session...

Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a...

Ionis Pharmaceuticals, Inc. today announced the completion of enrollment and positive preliminary findings from Part 1 of the...

This first presentation of non-human primate (NHP) data highlights the potential of Chroma's epigenetic editors to achieve specific and robust results after a single administration, without cutting or nicking the DNA In NHPs, Chroma's epigenetic...

The severely disabled and treatment-refractory patient was discharged without symptoms three weeks after KYV-101 infusion and was fully mobile 60 days after, with no observed adverse events related to CAR T-cell therapy The late breaker abstract was...

A post hoc analysis from the EXXELERATE Phase 4 trial showed that 65.7 percent of CIMZIA-treated patients with rheumatoid arthritis (RA) and high rheumatoid factor (RF) levels achieved low disease activity at Week 1041CIMZIA maintained drug...

Real-world evidence (RWE) leader Target RWE announced today that the CQC and TARGET-Liver Disease (LD) partnership with the American Association for the Study of Liver Diseases (AASLD) has enrolled approximately 75,000 patients....

Resonant, a subsidiary of Renew Biotechnologies aimed at releasing novel diagnostics for neurodegenerative diseases, recently published research revealing a novel blood biomarker of neurodegeneration. The technology achieved a remarkable 100%...

In a breakthrough for human milk science, researchers at City of Hope, Los Angeles, have...

Amgen  today announced new data reinforcing the safety and efficacy of Repatha® (evolocumab) from the...

Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, announced today that it has entered into a clinical collaboration agreement with F. Hoffmann-La Roche Ltd (Roche) to study...

debra of America, the leading patient advocacy organization dedicated to improving the quality of life for those living with Epidermolysis Bullosa (EB), raised $600,000 at its annual benefit on November 4, 2023, in Atlanta at the Georgia Aquarium....

Blueprint Medicines Corporation  today announced the Committee for Medicinal Products for...

One Retrospective Cohort, One Prospective Cohort, in Total of ~2,400 Cancer Patients and Non-cancer Individuals Demonstrate the Performance of SeekInCare Test to Detect Multiple Cancer Types and Predict Tissue of Origin of Cancers The Achievement of...

Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for RZ-001, for...

Mirati Therapeutics, Inc.® , a commercial stage biotechnology company, today announced that following a re-examination procedure, the Company has received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Products...

Kazia Therapeutics Limited , an oncology-focused drug development company, is pleased to announce the publication in Molecular Cancer Therapeutics highlighting paxalisib preclinical data stemming from the research collaboration with the Huntsman...

UCB, a global biopharmaceutical company, today announced new long-term data from the BIMZELX® (bimekizumab) Phase 2b study BE AGILE and its open-label extension (OLE). Patients with ankylosing spondylitis (AS) treated with BIMZELX, an IL-17A and...

Servier will showcase new data from its vorasidenib clinical development program in a plenary townhall at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO), November 16-19, 2023,...

Psoriatic disease, recognized as a serious noncommunicable disease by the World Health Organization (WHO), impacts millions worldwide. A pioneering advocacy tool, the Psoriatic Disease Response Index, has emerged to facilitate a vital policy...

On October 26, 2023, SyMap Medical invited Professor Felix Mahfoud, Vice-Chair of the Working Group Interventional Hypertension Treatment of the European Society of Hypertension (ESH) and a distinguished authority in the renal denervation (RDN)...

On November 9, 2023, ImmVira announced the successful completion of Phase I clinical study conducted on late-stage patients with various tumor types for our intravenous oncolytic product, MVR-T3011 IV, in the United States. This milestone was marked...

Bio-Botanica, Inc., ® the one American company that has manufactured botanical extracts under one family for more than 50 years, has revealed the results of clinical trials indicating its proprietary botanical extract ingredient, Puresterol®...

Based upon progress in its allogeneic programs, the Company is announcing today acceleration and increased certainty of achieving upcoming milestones and payments related to the Roche Collaboration Closed strategic investment by Astellas Pharma in...

Neurocrine Biosciences, Inc. , a leading neuroscience-focused biopharmaceutical company, today announced Phase 2 study results from two signal-seeking pipeline...

illumiSonics, Inc. announces the publication of a landmark clinical validation study in breast cancer diagnosis. The study was recently published in Current Oncology. This pioneering work, led by Dr. Parsin Haji Reza, chief scientific officer, marks...

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced today the first publication of a paper in Nature Communications on the development and validation of its NULISA technology. The...

Ionis Pharmaceuticals, Inc. today announced positive results from an ongoing Phase 2 open-label extension (OLE) study evaluating the safety and efficacy of its investigational...

Bryn Pharma, LLC, a privately held pharmaceutical company...

Remedee Labs, a French start-up that...

NeuroSense Therapeutics Ltd. ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced scientific presentations at three upcoming conferences. Neuroscience 2023 Mr. Nitai Kerem, NeuroSense's Scientific...

Suvoda LLC, a leading global clinical trial technology company specializing in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, has successfully conducted usability testing of its electronic clinical...

Lucid Diagnostics Inc.  ("Lucid" or the "Company") a commercial-stage, cancer prevention medical...

GBP510, a recombinant vaccine against COVID-19, adjuvanted with AS03, has shown to be highly immunogenic and well tolerated in healthy adults. Researchers from Korea conducted a clinical trial to assess the immunogenicity and safety of GBP510/AS03...

Ichnos Sciences, a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, today announced that three abstracts highlighting data on its leading oncology assets have been selected for presentation at...

Discover an informative webinar to unravel the complexity of the Clinical Trials...

Artivion, Inc. , a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed enrollment in the PERSEVERE clinical trial....

Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today announced the initiation of a randomized Phase 2 trial to evaluate the efficacy and safety of TTX-030, a potential first-in-class, anti-CD39 antibody. The...

Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of T Cell-mediated diseases, today announces that the United Kingdom's...

PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company focused on developing novel...

Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, announced today that their first patient has been successfully dosed in Taiwan Phase II...

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Dr. Samarendra Mohanty, President and Chief Scientific...

Oncolytics Biotech® Inc. , a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab in...

March Biosciences (March Bio), a clinical stage biotechnology company committed to combating challenging cancers unresponsive to existing immunotherapies, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The...

Oncolytics Biotech® Inc. (Oncolytics) , a clinical-stage immunotherapeutics company focused on oncology, provided an update on the planned program for...

uMotif ? one of the clinical research technology market's fastest growing companies ? announced today a partnership with cognitive science leaders Cogstate Limited . The collaboration brings...

Suvoda LLC, a leading global clinical trial technology company specializing in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, has successfully conducted usability testing of its electronic clinical...

In the ongoing battle against the fentanyl epidemic, a promising new approach has emerged and AltaPointe Health is at the forefront. AltaPointe's Behavioral Health Crisis Center (BHCC) has started offering the use of ketamine to help transition a...

A team led by researchers at NYU Langone Health has built nine new synthetic yeast chromosomes, swapping out a key organism's genetic material for engineered replacements....

Jana Care, Inc., the pioneering developer of at-home self-administered testing technologies for chronic kidney and heart disease management, today...